EBITDA Margin % is calculated as EBITDA divided by its Revenue. TherapeuticsMD's EBITDA for the
three
months ended in Mar. 2026 was $-0.63 Mil. TherapeuticsMD's Revenue for the
three
months ended in Mar. 2026 was $0.72 Mil. Therefore, TherapeuticsMD's EBITDA margin for the quarter that ended in Mar. 2026 was -86.88%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
TherapeuticsMD EBITDA Margin % Related Terms
TherapeuticsMD EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for TherapeuticsMD's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TXMD vs CPHI, RMTI, AYTU: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, TherapeuticsMD's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TherapeuticsMD EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TherapeuticsMD's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where TherapeuticsMD's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TherapeuticsMD (TXMD) has a EBITDA Margin % of -86.88% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on TherapeuticsMD and its competitors. According to the industry distribution chart, TherapeuticsMD ranks #873 out of 952 companies in the Drug Manufacturers industry, placing it in the top 91.7%.
Is TherapeuticsMD's EBITDA Margin % too high?
TherapeuticsMD's current EBITDA Margin % is -86.88%. Based on the distribution chart, TherapeuticsMD ranks #873 out of 952 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, TherapeuticsMD has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does TherapeuticsMD's EBITDA Margin % compare to CPHI and RMTI?
According to the Drug Manufacturers industry distribution chart, TherapeuticsMD ranks #873 out of 952 companies for EBITDA Margin %. This places TherapeuticsMD in the lower half of its industry. The industry median EBITDA Margin % is 12.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on TherapeuticsMD and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TherapeuticsMD's current EBITDA Margin % is -86.88%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TherapeuticsMD stock overvalued right now?
Based on GuruFocus' analysis, TherapeuticsMD (TXMD) is currently considered Fairly Valued. The stock's GF Value™ is $2.07, compared to a current price of $2.23 — trading 7.5% above its estimated fair value. The current EBITDA Margin % is -86.88%. TherapeuticsMD's overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For TherapeuticsMD (TXMD), the current EBITDA Margin % is -86.88% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TherapeuticsMD (TXMD) Overvalued in 2026?
Based on GuruFocus' analysis, TherapeuticsMD stock appears to be overvalued.
The current stock price of $2.23 is trading 7.5% above its estimated GF Value™ of $2.07.
GuruFocus considers TherapeuticsMD to be Fairly Valued.
Key valuation signals for TXMD:
EBITDA Margin %: -86.88%
GF Value™: $2.07 vs. price of $2.23 (7.5% above fair value)
No single metric tells the full story. See the TXMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.
54GF Score
Get the complete analysis for TXMD
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TXMD has been successfully added to your 
